Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023
Ralf Otto-Knapp, Suzanne Edwards, Giorgi Kuchukhidze, Stefan Kröger, Brit Häcker, Stela Bivol, Askar Yedilbayev
Abstract
The BPaLM regimen (bedaquiline, pretomanid, linezolid and moxifloxacin) recently recommended by the World Health Organization offers short, safe, and effective treatment for multidrug-resistant/rifampicin-resistant tuberculosis (TB). In a survey with national TB focal points in 18 central and western European countries to explore barriers for the implementation of BPaLM, only three reported full availability of pretomanid, a necessary component of this regimen. Implementation barriers included financing and procurement. Solutions on national and supranational level are needed to guarantee universal access.
Topics & Concepts
BedaquilineMoxifloxacinRegimenLinezolidTuberculosisRifampicinMedicineMultiple drug resistanceBusinessIntensive care medicineDrug resistanceInternal medicineAntibioticsMycobacterium tuberculosisPathologyBiologyVancomycinMicrobiologyBacteriaGeneticsStaphylococcus aureusTuberculosis Research and EpidemiologyPneumocystis jirovecii pneumonia detection and treatmentHIV/AIDS drug development and treatment